DCVC BIO
270 University AvenuePalo Alto, CA 94301
Firm Size
- Assets Under Management (AUM):$1.2 Billion
- Number of Funds:4
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
DCVC Bio is a venture capital firm based in Palo Alto, California. The firm focuses on investing in breakthrough biotechnology companies that aim to have a significant impact on the world's most pressing healthcare and life science challenges. DCVC Bio combines deep technical and scientific expertise with a strong investment track record to identify and support companies with the potential to transform multiple industries, including therapeutics, diagnostics, synthetic biology, and agricultural technologies. The firm's portfolio includes companies working on innovative solutions to diseases, drug discovery platforms, and advancements in genetic engineering. With its extensive network and resources, DCVC Bio actively partners with its portfolio companies throughout their growth journey, offering strategic guidance and operational support.Latest News
Powered by
Jan 24, 2024: Elo Life Systems Announces Oversubscribed $20.5 Million Series A2 Funding Round
Elo Life Systems , the next-generation ingredient company reimagining the future of food, today announced its oversubscribed Series A2 financing round, raising $20.5 million .
Dec 15, 2023: Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman , Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data.